Glen Burnie, MDNCT05795465Now EnrollingIRB Ready

Acute Respiratory Distress Syndrome Clinical Trial in Glen Burnie, MD

Access cutting-edge acute respiratory distress syndrome treatment through this phase 2 clinical trial at a research site in Glen Burnie. Study-provided care at no cost to qualified participants.

Sponsored by GEn1E Lifesciences

Quick Self-Assessment

See if you qualify for this Glen Burnie location

Preparing your pre-screening questions…

Expert Care in Glen Burnie

Access acute respiratory distress syndrome specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related acute respiratory distress syndrome treatment provided free

Apply for This Glen Burnie Location

Check if you qualify for this acute respiratory distress syndrome clinical trial in Glen Burnie, MD

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Glen Burnie

    Convenient for MD residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Glen Burnie site if eligible
  4. 4Begin participation

About This Acute Respiratory Distress Syndrome Study in Glen Burnie

GEn1E-1124-002 is a two-part Phase 2 study to evaluate the safety and tolerability of GEn-1124 in subjects with ARDS. Treatment with IV infusion dosing as early as possible after ARDS diagnosis. Subjects will be given a second dose approximately 8 hours after the first dose and will continue with twice daily dosing (BID regimen) for 5 days.

Sponsor: GEn1E Lifesciences

Who Can Participate

Inclusion Criteria

Male or female subject between the ages of 18 and 85 years old, inclusive.
Written informed consent .
Dosing as early as possible after first meeting ARDS 2023 Global definition.
Acceptable method of birth control.

Exclusion Criteria

Subject, surrogate, or physician not committed, or eligible, to receive full supportive care measures.
Pregnant or breastfeeding
Currently incarcerated in a correctional institution or involuntarily committed to an inpatient mental health facility.
Active malignancy (other than non-melanoma skin cancer) requiring treatment with immunosuppressant drugs within the last 3 months or within the last 6 months if an anti-B cell antibody was received.
Any other irreversible disease or condition for which 6-month mortality is estimated to be \>50%.
Moderate to severe liver failure.
Estimated glomerular filtration rate (eGFR) \<10 mL/min/1.73 m2 or requiring dialysis at screening.
Subjects with known:
New York Heart Association Class IV heart disease; or
Acute Coronary Syndrome within the past 30 days (e.g., myocardial infarction, unstable angina) or dosing; or
Cardiac arrest within 30 days of dosing with sequelae likely to increase mortality.
Severe chronic respiratory disease with continuous home oxygen \>2 liters per minute (LPM) or \>28% (adjusted for altitude); and/or home noninvasive ventilation (except for the treatment of obstructive sleep apnea).
Poly-traumatic injury resulting in significant blood loss and/or likely to require major surgery within the study period, or subject condition that would interfere with study procedures.
History of any type of solid organ or cellular transplant.
Receiving immunosuppressive therapy for solid organ or hematopoietic cancer, transplant anti-rejection medication, and/or other chronic conditions.
Moribund subject not expected to survive 24 hours.
Do not resuscitate (DNR) status.
World Health Organization (WHO) functional class III or IV pulmonary hypertension.
Subject has been on mechanical ventilation for more than 7 days at time of dosing.
Burn victims currently undergoing treatment for \>40% total body surface area (TBSA) involvement or for known airway inhalation injury.
Neuromuscular disease that could impact ability to wean from mechanical ventilation.
History of tuberculosis (TB); undergoing treatment for latent TB infection (LTBI); untreated LTBI (as determined by documented results within 3 months of Screening of a positive TB test).
Active Hepatitis B, positive Hepatitis C (and has not completed antiviral treatment), or positive human immunodeficiency (HIV) screen.
Use of any investigational drug or device within last 30 days of dosing or 5 half-lives, whichever is longer.
Any other medical, psychiatric, or social condition that, in the opinion of the investigator, is likely to unfavorably alter the risk-benefit of subject participation, to interfere with protocol compliance, or to confound safety.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Glen Burnie?

Yes, this clinical trial (NCT05795465) has an active research site in Glen Burnie, MD that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Acute Respiratory Distress Syndrome Treatment Options in Glen Burnie, MD

If you're searching for acute respiratory distress syndrome treatment options in Glen Burnie, MD, this clinical trial (NCT05795465) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Glen Burnie research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced acute respiratory distress syndrome specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all acute respiratory distress syndrome clinical trials near you to find additional studies recruiting in your area.

More Rheumatoid Arthritis Trials in Glen Burnie, MD

See all rheumatoid arthritis clinical trials recruiting in Glen Burnie — not just this study.

Browse Rheumatoid Arthritis Trials in Glen Burnie →

Browse More Trials by Condition

Rheumatoid Arthritis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Glen Burnie?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Glen Burnie, MD